This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Biedenbach, D. J.
Right arrow Articles by Jones, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Biedenbach, D. J.
Right arrow Articles by Jones, R. N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2009, p. 1260-1263, Vol. 53, No. 3
0066-4804/09/$08.00+0     doi:10.1128/AAC.01453-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Activities of Dalbavancin against a Worldwide Collection of 81,673 Gram-Positive Bacterial Isolates{triangledown}

Douglas J. Biedenbach,1* Jan M. Bell,2 Helio S. Sader,1 John D. Turnidge,2 and Ronald N. Jones1

JMI Laboratories, North Liberty, Iowa,1 Women's and Children's Hospital, North Adelaide, Australia2

Received 30 October 2008/ Returned for modification 19 December 2008/ Accepted 26 December 2008

Dalbavancin, a long-acting lipoglycopeptide, was evaluated against 81,673 isolates of staphylococci, enterococci, and streptococci collected from 33 countries during worldwide resistance surveillance (2002 to 2007). Regardless of susceptibility to oxacillin, comparable potencies for dalbavancin against Staphylococcus aureus and coagulase-negative staphylococci from all countries were noted (MIC90, 0.06 to 0.12 µg/ml). Vancomycin-susceptible Enterococcus spp. had dalbavancin MIC90s comparable to those for staphylococci, whereas vancomycin-resistant strains were more resistant (MIC50, >4 µg/ml). β-Hemolytic and viridians group streptococci were very susceptible to dalbavancin (MIC90, ≤0.03 µg/ml). Overall, dalbavancin was ≥16-fold more active than vancomycin against the monitored gram-positive species.

* Corresponding author. Mailing address: JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317. Phone: (319) 665-3370. Fax: (319) 655-3371. E-mail: douglas-biedenbach{at}jmilabs.com

{triangledown} Published ahead of print on 5 January 2009.

Antimicrobial Agents and Chemotherapy, March 2009, p. 1260-1263, Vol. 53, No. 3
0066-4804/09/$08.00+0     doi:10.1128/AAC.01453-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Arhin, F. F., Draghi, D. C., Pillar, C. M., Parr, T. R. Jr., Moeck, G., Sahm, D. F. (2009). Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates. Antimicrob. Agents Chemother. 53: 4762-4771 [Abstract] [Full Text]  
  • Caspers, P., Bury, L., Gaucher, B., Heim, J., Shapiro, S., Siegrist, S., Schmitt-Hoffmann, A., Thenoz, L., Urwyler, H. (2009). In Vitro and In Vivo Properties of Dihydrophthalazine Antifolates, a Novel Family of Antibacterial Drugs. Antimicrob. Agents Chemother. 53: 3620-3627 [Abstract] [Full Text]  
  • Vandecasteele, S. J., Boelaert, J. R., De Vriese, A. S. (2009). Staphylococcus aureus Infections in Hemodialysis: What a Nephrologist Should Know. CJASN 4: 1388-1400 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»